Lundbeck to buy Longboard Pharma in $2.6 billion deal
14/10/2024 11:35
Oct 14 (Reuters) - H Lundbeck A/S HLUNb.CO has agreed to buy US-based Longboard Pharmaceuticals LBPH.O in a $2.6 billion deal to boost its pipeline of treatments for neuro-rare conditions, the companies said on Monday. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions